Lupin Ltd. Sees Significant Open Interest Surge Amidst Mixed Market Signals

Open Interest and Volume Dynamics

The latest data reveals Lupin’s open interest rising from 29,853 contracts to 33,831, an increase of 3,978 contracts. This 13.33% jump in OI accompanies a daily volume of 26,336 contracts, indicating robust participation in the derivatives market. The futures segment alone accounts for a value of approximately ₹89,198 lakhs, while options contribute a staggering ₹17,696.45 crores, culminating in a total derivatives value of ₹90,835 lakhs. Such elevated figures underscore the growing interest in Lupin’s price movements among traders and institutional investors alike.

Price Performance and Market Context

On the price front, Lupin closed at ₹2,348, just 1.01% shy of its 52-week high of ₹2,377.6. The stock has recorded gains over the past two consecutive sessions, delivering a cumulative return of 2.49%. However, it has underperformed its sector benchmark, which advanced by 2.35% on the same day, and lagged behind the broader Sensex gain of 2.25%. This relative underperformance, despite positive price momentum, suggests selective profit-taking or cautious positioning by investors.

Further technical validation comes from Lupin trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a sustained uptrend. The rising delivery volume of 8.36 lakh shares on 24 March, a 46.78% increase over the five-day average, confirms growing investor participation in the underlying equity, reinforcing the derivatives market activity.

Market Positioning and Directional Bets

The surge in open interest alongside rising volumes typically indicates fresh positions being established rather than old ones being squared off. In Lupin’s case, the increase in OI coupled with a modest price rise suggests that traders are building directional bets, possibly anticipating further upside. However, the stock’s slight underperformance relative to the sector and the broader market hints at a cautious stance, with some participants hedging their exposure or awaiting clearer catalysts.

Given Lupin’s mid-cap status with a market capitalisation of ₹1,07,583.40 crores and a Mojo Score of 78.0, the stock remains favoured by analysts, though its Mojo Grade was recently downgraded from Strong Buy to Buy on 16 February 2026. This adjustment reflects a tempered optimism, balancing Lupin’s solid fundamentals against near-term market uncertainties.

Sector and Liquidity Considerations

Lupin operates within the Pharmaceuticals & Biotechnology sector, which has shown resilience with a 2.35% gain on the day. Despite Lupin’s slight underperformance, the sector’s strength provides a supportive backdrop for the stock’s medium-term prospects. The stock’s liquidity profile is robust, with the ability to handle trade sizes of up to ₹4.8 crores based on 2% of the five-day average traded value, making it attractive for institutional investors and active traders.

Implications for Investors

The combination of rising open interest, increasing delivery volumes, and Lupin’s position near its 52-week high suggests that investors are positioning for potential upside while remaining mindful of risks. The downgrade from Strong Buy to Buy indicates a cautious recalibration of expectations, possibly due to sector headwinds or valuation concerns. Investors should monitor upcoming earnings, regulatory developments, and sector trends closely to gauge the sustainability of Lupin’s momentum.

Technical and Fundamental Outlook

From a technical perspective, Lupin’s trading above all major moving averages confirms a bullish trend, supported by steady volume and open interest growth. Fundamentally, the company’s mid-cap status and strong Mojo Score of 78.0 reflect solid financial health and growth potential. However, the recent grade change signals that while Lupin remains a buy, investors should be prepared for possible volatility or consolidation phases.

Conclusion: Navigating Lupin’s Derivatives Activity

The recent surge in Lupin’s open interest and volume in the derivatives market highlights a phase of active repositioning by traders and investors. While the stock’s price gains have been modest and slightly lagging the sector, the underlying technical strength and increased investor participation suggest a cautiously optimistic outlook. Market participants should watch for confirmation of directional trends through upcoming earnings announcements and sector developments.

Given the mixed signals, Lupin remains a compelling stock for investors favouring mid-cap pharmaceuticals, but with a recommendation to maintain vigilance on market cues and valuation metrics. The downgrade to a Buy rating reflects this balanced view, encouraging investors to weigh potential rewards against emerging risks carefully.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today